MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WAYMIRE, J. C.
Right arrow Articles by HAYCOCK, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WAYMIRE, J. C.
Right arrow Articles by HAYCOCK, J. W.

Molecular Pharmacology, Vol 15, 78-85, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

Induction of Tyrosine Hydroxylase and Dopamine beta-Hydroxylase in Cultured Mouse Neuroblastoma by 8Br-cAMP

Involvement of RNA and Protein Synthesis

J. C. WAYMIRE 1, K. GILMER-WAYMIRE 1, D. NORITAKE 1, G. GIBSON 1, D. KITAYAMA 1, and J. W. HAYCOCK 1

1 Department of Psychobiology, School of Biological Sciences, University of California, Irvine, California 92717

8Br-cAMP elevated tyrosine hydroxylase (E.C. 1.14.16.2, L-tyrosine, tetrahydropteridine: oxygen oxidoreductase [3-hydroxylating]) and dopamine beta-hydroxylase (E.C. 1.14.17.1, 3,4-dihydroxyphenylethylamine, ascorbate:oxygen oxidoreductase [beta-hydroxylating]) activities in neuroblastoma clone NBD-2 from the mouse C-1300 tumor. The increase in activities was associated with a 5-10 fold increase in the Vmax of both enzymes for both substrate and cofactor. Immunoprecipitation of tyrosine hydroxylase in control and treated cells demonstrated that more immunoprecipitable enzyme was present in the treated samples. Maximal elevation of both tyrosine hydroxylase and dopamine beta-hydroxylase occurred after 48 hr of treatment with 1.0 mM 8Br-cAMP. Actinomycin D (0.1 µg/ml), cycloheximide (2.0 µ/ml) and lysine-deficient medium prevented the 8Br-cAMP elevation of enzyme activity. However, removal of cycloheximide or subsequent addition of lysine (even with simultaneous addition of actinomycin D) allowed the subsequent elevation of enzyme activity. The rate of increase in enzyme activity did not exhibit the lag period typically observed in cells treated only with 8Br-cAMP. These data suggest that cAMP elevates the level of tyrosine hydroxylase and dopamine beta-hydroxylase protein and that an increased production of messenger RNA may be one of the steps necessary for these effects.

Submitted on July 10, 1978
Accepted on August 11, 1978







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics